Seroprotection rate, mean fold increase, seroconversion rate:: which parameter adequately expresses seroresponse to influenza vaccination?

被引:155
作者
Beyer, WEP
Palache, AM
Lüchters, G
Nauta, J
Osterhaus, ADME
机构
[1] Erasmus Univ, Nat Infleunza Ctr, Dept Virol, NL-3000 DR Rotterdam, Netherlands
[2] Solvay Pharmaceut, Weesp, Netherlands
[3] Univ Bonn, D-5300 Bonn, Germany
关键词
influenza; vaccine; inactivated; antibody response; data analysis; statistics;
D O I
10.1016/j.virusres.2004.02.024
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Serological parameters intend to describe antibody response to influenza vaccine in a population. However, there is uncertainty about the mathematical appropriateness and the biological or clinical meaning of conventionally used parameters. Theoretical considerations and exploration of a data-set of 16 studies with an inactivated (subunit) influenza vaccine involving 1176 adult subjects suggest the following conclusions. In a population seronegative before vaccination, the post-vaccination geometric mean titre (post-GMT) is a meaningful immunological parameter adequately expressing antibody response after vaccination. The related protection rate (PR) is a good surrogate parameter for protection provided by a given vaccine, thus relevant to public health. However, in a population partially seropositive before vaccination (due to previous exposition to influenza antigens), the same parameters may, under certain conditions, seriously overestimate the antibody response, as they do not account for the pre-vaccination state. Conventional attempts to address pre-vaccination antibody are associated with either loss of information (exclusion of seropositive subjects) or incomplete control of pre-vaccination state (mean fold increase (MFI), response rate (RR)). Although not devoid of theoretical limitations (heteroscedasticity), correction of post-GMT and PR by linear regression appears to provide better estimates of antibody response and vaccine immunogenicity. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:125 / 132
页数:8
相关论文
共 16 条
  • [1] Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines - A review and meta-analysis of the literature
    Beyer, WEP
    Palache, AM
    Osterhaus, ADME
    [J]. CLINICAL DRUG INVESTIGATION, 1998, 15 (01) : 1 - 12
  • [2] Protection against influenza after annually repeated vaccination -: A meta-analysis of serologic and field studies
    Beyer, WEP
    de Bruijn, IA
    Palache, AM
    Westendorp, RGJ
    Osterhaus, ADME
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (02) : 182 - 188
  • [3] ANTIBODY INDUCTION BY INFLUENZA VACCINES IN THE ELDERLY - A REVIEW OF THE LITERATURE
    BEYER, WEP
    PALACHE, AM
    BALJET, M
    MASUREL, N
    [J]. VACCINE, 1989, 7 (05) : 385 - 394
  • [4] Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy A meta-analysis
    Beyer, WEP
    Palache, AM
    de Jong, JC
    Osterhaus, ADME
    [J]. VACCINE, 2002, 20 (9-10) : 1340 - 1353
  • [5] Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults
    Beyer, WEP
    Palache, AM
    Sprenger, MJW
    Hendriksen, E
    Tukker, JJ
    Darioli, R
    vanderWater, GL
    Masurel, N
    Osterhaus, ADME
    [J]. VACCINE, 1996, 14 (14) : 1331 - 1339
  • [6] *CPMP, 1992, RUL GOV MED PROD EUR, V3, P93
  • [7] *CPMP, 1997, NOT GUID HARM REQ IN, P15
  • [8] DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS, P173
  • [9] de Jong J C, 2003, Dev Biol (Basel), V115, P63
  • [10] USES AND ABUSES OF ANALYSIS OF COVARIANCE IN CLINICAL-TRIALS
    EGGER, MJ
    COLEMAN, ML
    WARD, JR
    READING, JC
    WILLIAMS, HJ
    [J]. CONTROLLED CLINICAL TRIALS, 1985, 6 (01): : 12 - 24